News

Why peripheral blood lymphocyte alterations can be good biomarkers to predict myocardial infarction severity

Researchers of CCMIJU led by Verónica Crisóstomo, Scientific Director of NANBIOSIS U24 Medical imaging, and Javier García Casado Scientific Director of NANBIOSIS U14 Cell Therapy unit have carried out a study study aimed to identify which are the very early immune-related biomarkers that may be used as predictors of myocardial infarction severity.

Experimental studies have been conducted by NANBIOSIS Units 14, 21, 22 and 24 of the CCMIJU, clinical test lab, animal housing, experimental operating room and medical imaging tecniciansare are recognized in the acknowledgement and funding sections of the article.

Article of reference:

Esther López, Francisco Miguel Sánchez-Margallo, Verónica Álvarez, Rebeca Blázquez, Federica Marinaro, Ana Abad, Helena Martín, Claudia Báez,Virginia Blanco,Verónica Crisóstomo and Javier García Casado “Identification of very early inflammatory markers in a porcine myocardial infarction model” BMC Veterinary Research 2019-15:91

• Read More

New tensiometer for NANBIOSIS Unit 12

The new Biolin Sigma 701 has replaced the previos KSV Sigma 700. in the equipment of NANBIOSIS U12 Nanostructured liquid characterization unit

With this new tensiometer automated and high precision measurement of surface and interfacial tensions, contact angles and critical micelle concentrations will be obtained.

The purchase of the new tensiometer has been co-funded by the CSIC through a grant received from the Scientific and Technical Services support (MEC1372).

• Read More

Infertility: Exosomal microRNAs in seminal plasma as sensitive and specific biomarkers of the presence of testicular spermatozoa for azoospermia

NANBIOSIS ICTS coordination equipment has recently received from researchers of Human Molecular Genetics Group of Bellvitge Biomedical Research Institute (IDIBELL) a publication mentioning NANBIOSIS in the Acknowledgements for its participation in the results of its investigations. The article has been publish by the journal Human Reproduction of OXFORD UNIV PRESS with Quartile 1/ Decile 1.

The study carried out by Maria Barcelo, Ana Mata, Lluís Bassas, and Sara Larriba demonstrates the potential of several miRNAs contained in small extracellular vesicles (sEVs) of seminal fluid as sensitive and specific biomarkers for selecting those azoospermic individuals with real chances of obtaining spermatozoa from the testicular biopsy. The nanoparticle tracking analysis was performed by the ICTS NANBIOSIS U6 Biomaterial Processing and Nanostructuring Unit.

Article of reference:

Maria Barceló, Ana Mata, Lluís Bassas and Sara Larriba, Exosomal microRNAs in seminal plasma are markers of the origin of azoospermia and can predict the presence of sperm in testicular tissue Human Reproduction, pp. 1–12, 2018doi:10.1093/humrep/dey072

• Read More

Micro & nano(bio)technology for Diagnosis: Changes and Challenges

Pilar Marco, Scientific Director of NANBIOSIS U2 Custom Antibody Service (CAbS) participated as Keynote speakers at the Second European Biosensor Symposium (EBS2019) taking about “Micro & nano(bio)technology for Diagnosis: Changes and Challenges” at the 2nd European Biosensor Symposium 2019 that took place in Florence (Italy) Last February 18-21.

The EBS brougth toguether young scientists, experienced researchersand companies to push forward new approaches on biosensor and and their applications,

Pilar Marco spoke abaut the changes ocurred on the field of Diagnosis since the days of “house calls”, relying primarily on physical examination, to nowadays in which a wide portfolio of biochemical analytical tests is available, and pointed out the challenge to improve knowledge in microfluidics, lab-on-a-chip technologies, system integration, device automation, and signal readout, as well as simultaneously measure distinct sets of biomolecular features on a reproducible and reliable manner. Prof. Marco also gave some examples of technological alternatives to circumvent these limitations in the clinical diagnostic field.

Pictures by Rudolf Schneider https://bit.ly/2T0yYNi

• Read More

The European Union highlights the relevance of the JUMISC’s Cutting-Edge Infraestructures and Technology, recognized as ICTS.

Jesús Usón Minimally Invasive Surgery Center (JUMISC), from Cáceres, partnert of NANBIOSIS, has recently made headlines on the website of the European Commission as an innovative center for Biomedical and Health Research.

In the interview to his Director, Francisco Miguel Sanchez Margallo, he explained how European Funds allowed Infraestructures and Vanguard Technology for biomedical research at the CCMIJU, which have already been recognized, as part of NANBIOSIS, with CIBER-BBN and BIONAND, as “Singular Scientific and Technical Infrastructure” (ICTS).

Complete news at European Commision’s Website: https://ec.europa.eu/spain/news/investeu_caceres_es

https://ec.europa.eu/spain/news/investeu_caceres_es

• Read More

GLP Analytical Validation Study in Different Animal Species

Beatriz Moreno Lobato and Francisco Miguel Sánchez Margallo, Scientific Director and Coordinator of NANBIOSIS unit 19 Clinical tests lab at CCMIJU, have reclently published an study in the journal Thrombosis & Haemostasis: Research, with the aim to contribute with methodological results data to help the researcher to establish the validation of the analytical methods used within the research.

Good Laboratory Practice (GLP) is a quality system of management controls to ensure the uniformity, consistency, reliability, reproducibility, quality, and integrity of pre-clinical safety tests.

In the study, different hematological parameters (WBC, RBC, HB, HCT, MCV, MCH, MCHC, and PLT) were validated in pig, sheep, dog and rabbit, calculatting the repeatability and the intermediate precision . The obtained results were statistically analyzed; the mean, the standard deviation and the coefficient of variation were calculated.

The study results ensure the quality and integrity of the measurements obtained in the CCMIJU Clinical tests lab (unit 19 of NANBIOSIS), which is necessary in the performance of preclinical studies.

Article of reference: Moreno-Lobato B and Sánchez-Margallo FM. Analytical Validation Study of Hematological Parameters under Good Laboratory Practice Regulations in Different Laboratory Animal Species. Thromb Haemost Res. 2019; 3(1): 1018.

• Read More

PILAR MARCO, Scientific Director of NANBIOSIS U2, interviewed by CIBER-BBN ISCIII Bulletin

Pilar Marco, Scientific Director of NANBIOSIS U2 Custom Antibody Service (CAbS) has been highlighted in the January Bulletin of CIBER-BBN ISCIII

In the interview, among other topics Prof. Pilar Marco talks about diagnostic devices based on nanobiosensors and the extraordinary impact that these technologies could have on health in the coming decades.

Her research group Nb4D (Nanobiotechnology for Diagnosis) has an important collection of specific antibodies for different biomarkers and the CIBER-BNN/IQAC-CSIS platform CAbS (Custom Antibody Service) that constitutes the unit 2 of NANBIOSIS, they offer the possibility of producing specific and immunoreactive antibodies with the necessary expertise to generate antibodies “a la carte”, that is, being able to modulate to some extent the affinity and selectivity of these biomolecules, depending on the needs of each project. “And we do this, -Prof Marco explains- not only for molecules with high immunogenic capacity such as most proteins, but also for low molecular weight molecules, which in themselves are not capable of generating an immune response”. They are also able to chemically modify these antibodies and bind them to nanoparticles with defined optical, electrochemical or magnetic properties, thus converting them into nanoprobes able to detect biomarkers and generate an optical or electrochemical signal. We can also incorporate them in a controlled manner in transducer devices designed based on the latest advances in micro (nano) electronics to develop a new generation of diagnostic devices, much more sensitive and reliable, capable of providing quick answers and allowing a more accurate diagnosis early and accurate.

• Read More

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology.

According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science.

NANBIOSIS wants to acknowledge the efforts made by scientific women who struggle every day to contribute their bit to Science and highlight their essential role in nowadays research. Especially we want to recognize the work of scientists women involved in our units, whatever is the nature of their contribution: technical, scientific development, management, coordination, direction, etc; just to mention some examples:
Neus Ferrer in the Scientific Direction of Unit 1 Protein Production Platform (PPP)
Pilar Marco and Nuria Pascual in the Management and Scientific Coordination of U2 Custom Antibody Service (CAbS)
Miriam Royo in the Scientific Direction of U3 Synthesis of Peptides Unit
Laura Lechuga and M.Carmen Estevez in the Direction and Scientific Coordination of U4 Biodeposition and Biodetection Unit
Nora Ventosa and Nathaly Segovia in the Scientific Direction and Technical Coordination of U6 Biomaterial Processing and Nanostructuring Unit
Isabel Oliveira and Teresa Galán in the Coordination of U7 Nanotecnology Unit
Rosa Villa and Gemma Gabriel in the Management and Scientific Coordination of U8 Micro – Nano Technology Unit
Gema Martínez in the Scientific Coordination of U9 Synthesis of Nanoparticles Unit
Fany Peña in the Scientific Coordination of U13 Tissue & Scaffold Characterization Unit
Mª Luisa González Martín in the of Direction and Scientific Coordination of U16 Tissue & Scaffold Characterization Unit
Gemma Pascual and Isabel Trabado in the Coordination of the U17 Confocal Microscopy Service
Mª Virtudes Céspedes in the Scientific Coordination of U18 Nanotoxicology Unit
Beatriz Moreno in the Scientific Direction of Unit 19 Clinical tests lab
Ibane Abásolo in the Scientific Coordination of Unit 20 In Vivo Experimental Platform t
Verónica Crisóstomo in the Scientific Direction of Unit 24 Medical Imaging

Ana Paula Candiota in the Scientific Coordination of Unit 25 Biomedical Applications I
Maria Luisa García in the Scientific Direction of U28 NanoImaging Unit from Bionand, recently incorporated to NANBIOSIS

• Read More

Label-free bacteria quantification in blood plasma by a bioprinted microarray based interferometric point-of-care device

Prof Laura Lechuga, Scientific Director of NANBIOSIS U4 Biodeposition and Biodetection Unit is coauthor of an article publish by ACS Sonsors that shows a portable and autonomous device based on optical interferometry that, when used with specialized nanoplasmonic, can detect directly bacterial cells of the patient’s blood plasma.

The work demonstrates the potential of a microarray based POC device for bacteria quantification. The contribution of NANBIOSIS, in particular Unit 4, has been fundamental by providing the molecular printers necessary for the generation of the biofunctionalized specific microarrayed chips used for the bacteria detection.

P. Dey, N. Fabri-Faja, O. Calvo-Lozano, R. Terborg, A. Belushkin, F. Yesilköy, A. Fàbrega, J. C. Ruiz-Rodriguez, R. Ferrer, J. J. González-López, M. C. Estévez, H. Altug, V. Pruneri, L. M. Lechuga. Label-free bacteria quantification in blood plasma by a bioprinted microarray based interferometric point-of-care device. ACS Sens., 2019, 4 (1), pp 52–60 DOI: 10.1021/acssensors.8b00789

• Read More

PICCOLO PROJECT FACE-TO-FACE MEETING

The 5th project face to face meeting has taken place in Cáceres (Spain). The first version of the PICCOLO prototype was set up at CCMIJU, facilities at the end of 2018, and it has been a great chance to show it to the PICCOLO consortium members. During these two days of the meeting, the technical partners presented both the individual components of the prototype (MPT and OCT) and the integration of the same in the probe of the multi-photonic system. The attendants have been able to check in-situ the performance of the prototype in the operating rooms of CCMIJU. Based on this, and in close collaboration with clinical partners, next steps regarding the pre-clinical tests on animal models to be performed were discussed.

This project has received funding from the European Union’s Horizon 2020 research and innovation Programmeunder Grant Agreement No. 732111

Image of the meeting participants at the face to face meeting in the JUMISC, partner of NANBIOSIS.

• Read More

You are here : Home / News